CASR Genotype

If a routine blood test has ever flagged your calcium as slightly high or slightly low, the usual next move is to hunt for a parathyroid problem. Sometimes the real explanation is written into a single gene you were born with.

CASR (the calcium-sensing receptor gene) sets how tightly your body holds blood calcium in range. Knowing your result can explain a confusing calcium reading, spare an unnecessary operation, and flag risk for close relatives who share your DNA.

The Calcium Thermostat

CASR carries the blueprint for the calcium-sensing receptor, a protein that sits on the surface of cells and constantly measures how much calcium is in your blood. It is made mostly in the parathyroid glands (four small glands in your neck) and in the kidneys.

When blood calcium rises, this receptor tells the parathyroid glands to release less PTH (parathyroid hormone, the signal that pushes calcium up) and tells the kidneys to send more calcium out in the urine. The net effect is a stable calcium level. A change in CASR shifts the setting on that thermostat.

Two Directions a Variant Can Push

CASR variants matter because they move the receptor in one of two directions. Some variants weaken it, so the body tolerates a higher calcium level before reacting, producing mild lifelong high calcium with unusually low calcium in the urine. Other variants make it too sensitive, so calcium runs low while the parathyroid glands stay quiet.

These two patterns map onto two named inherited conditions. Weakened, or loss-of-function, variants cause familial hypocalciuric hypercalcemia. Overactive, or gain-of-function, variants cause autosomal dominant hypocalcemia.

Familial Hypocalciuric Hypercalcemia (FHH1)

A loss-of-function CASR variant usually causes a mild, lifelong high blood calcium that rarely causes harm on its own. The catch is that it looks almost identical to primary hyperparathyroidism, a condition often treated with surgery. People with FHH1 have been sent for parathyroid operations they never needed.

In a large health system, FHH1 was found at roughly 74 cases per 100,000 people, similar to primary hyperparathyroidism. In one endocrine clinic evaluating families with high calcium, a CASR mutation was found in about 47 percent of cases overall, rising to about 87 percent when a blood relative also had high calcium; this comes from a single-clinic series rather than the general population.

When a child inherits severe loss-of-function variants from both parents, the result can be neonatal severe hyperparathyroidism, a dangerous newborn illness. This is why a family FHH1 result is relevant to pregnancy planning.

Autosomal Dominant Hypocalcemia (ADH1)

A gain-of-function CASR variant does the opposite, producing low blood calcium with low or inappropriately normal PTH, and often excess calcium spilling into the urine. This condition, ADH1, tends to be more symptomatic than FHH1 and carries the clearest signal for real complications.

In a systematic review of ADH1, 39 percent of people had seizures, and among those treated conventionally and assessed for complications, 75 percent had at least one. High urine calcium was strongly tied to kidney damage, kidney stones, calcium deposits in the kidney, or brain calcifications, with about nine times the odds of these problems compared with people whose urine calcium stayed lower.

There is a treatment twist that makes the diagnosis worth confirming. Standard calcium and active vitamin D therapy, given to raise a low calcium level, can push even more calcium into the urine and worsen kidney risk in ADH1. ADH1 appears at roughly 4 cases per 100,000 people and is frequently missed.

Common Variants and Everyday Calcium

Most people who carry a CASR change do not have a rare disease-causing mutation. They carry common variants such as A986S, R990G, or Q1011E, which nudge calcium regulation only slightly. In large population analyses, a common CASR variant explained only about 1 percent, or less, of the differences in serum calcium between people.

These common variants are best thought of as small modifiers, not diagnoses. In adolescents, the A986S variant was linked to slightly higher albumin-corrected calcium, while PTH did not differ meaningfully. Among kidney stone formers, a variant linked to R990G raised the chance of high urine calcium, while A986S tracked more with a small rise in blood calcium than with calcium excretion. For these common variants, standardized clinical cutpoints do not exist, so a single result is a hint about your calcium biology, not a verdict.

Kidney Stones

Because the receptor controls how much calcium the kidney dumps into urine, some CASR variants track with stone risk. A variant in the gene's promoter (the switch that controls how much receptor is made), rs6776158, was linked to higher calcium stone risk and lower receptor levels in kidney tissue. In dialysis patients, the rs7652589 A variant was associated with stone-related kidney failure and more severe overactivity of the parathyroid glands.

Chronic Pancreatitis

The R990G variant has been tied to a higher risk of chronic pancreatitis, an inflammatory scarring of the pancreas, in a US study where the association was strongest in people with moderate to heavy alcohol use, suggesting the variant and the exposure act together. This link is contested: two later European cohorts (one German and French, one Hungarian) found no association between common CASR variants and chronic pancreatitis, so the finding is not settled.

Pulmonary Hypertension

In idiopathic pulmonary arterial hypertension, a rare high-pressure disease of the lung arteries, the rs1042636 variant and related promoter variants were associated with higher susceptibility, higher lung artery pressure, and worse survival. This is a single-population signal supported by laboratory work, not an established clinical test.

Mixed and Site-Specific Cancer Signals

CASR variants show up in cancer studies, but the direction of risk flips depending on the disease and population. The rs1801725 variant was linked to higher colorectal cancer risk and worse survival mainly in Asian cohorts, yet larger studies in European populations found no overall colon cancer association. The rs17251221 variant appeared protective for ovarian cancer in one cohort, but a meta-analysis of multiple studies tied the same variant to higher breast and prostate cancer risk, so its overall effect is far from settled.

This looks contradictory only if you expect CASR to be a simple good-number or bad-number gene. It is not. CASR shifts the setting of a calcium-sensing system that behaves differently in different tissues, so the same variant can nudge one organ toward risk and another away from it. Most of these findings come from single populations and have not been consistently replicated, which is why none is used to guide cancer care today.

Why Your Genotype Does Not Predict Severity

A tempting mistake is to assume that once you know your CASR variant, you know how sick you will be. The evidence points the other way. Even relatives carrying the exact same variant can differ widely, from no symptoms with near-normal calcium to severe disease.

The strength of a variant's effect in a lab dish does not reliably match real-world severity. Large shifts in receptor sensitivity can be silent, while smaller shifts sometimes accompany serious disease. Genotype alone should not drive treatment or monitoring decisions; it has to be read alongside your actual calcium, PTH, and urine calcium.

When a Result Can Mislead

• Panel coverage: the test only detects the specific variants it is designed to find. A negative result does not rule out a rare CASR variant, or look-alike conditions caused by other genes such as GNA11 or AP2S1.
• Ancestry: many CASR associations and urine-calcium correlations were worked out mainly in people of European ancestry, so their meaning in other populations is less certain.
• Uncertain variants: an unexpected change may be reported as a variant of uncertain significance. Absence from a genetics database does not prove a variant is harmless, and presence does not prove it causes disease.
• Test grade: a clinical-grade result is interpreted differently from a consumer ancestry report that happens to cover the same spot in the gene.

A Result You Only Need Once

Your CASR genotype is fixed from birth and will read the same next year, so there is no trend to chase and no reason to repeat the test unless a lab needs to confirm an uncertain call by a second method. The value comes from acting on it over time, not from retesting it.

What does deserve ongoing tracking is the calcium biology downstream of the gene. If you carry a meaningful variant, blood calcium, PTH, and a urine calcium measurement are the numbers to follow, along with periodic kidney assessment in ADH1, on a schedule your clinician sets.

What an Unexpected Result Should Prompt

A CASR result is meant to be read together with a small cluster of companion tests: blood calcium, PTH, a 24-hour urine calcium, vitamin D, phosphorus, and kidney function. The combination is what tells a story, not the gene by itself.

A pattern of high blood calcium with low urine calcium plus a loss-of-function variant points toward FHH1 and is a strong reason to pause before any parathyroid surgery. Low blood calcium with high urine calcium plus a gain-of-function variant points toward ADH1, where standard calcium and vitamin D treatment needs extra caution. Either pattern is worth taking to an endocrinologist or medical geneticist, who can also arrange cascade testing for biological relatives and involve a genetic counselor.